Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Genzyme/Geltex Pharmaceuticals Joint Venture
Bruner, Robert F.; Bodily, Samuel E.; Jacquet, PierreCaso DARDEN-F-1254-EFinanzasIn March 1997, an executive vice president of Genzyme Corporation must develop the terms by which the $518 billion (revenue) firm will form a joint venture with a small biotechnology firm to make and market a new drug. The tasks for the decision maker are to estimate the enterprise value of the new joint venture, recommend how large an interest to acquire in the venture, and determine what price to pay for that interest and when. The case may be ...Desde 8,20 €
-
Kelly Solar - Teaching Note
Lipson, Marc L.; Bodily, Samuel E.; Lichtendahl, Kenneth C. Jr.Nota del Instructor DARDEN-F-1614TN-EFinanzasTeaching note for product F-1614Desde 0,00 €
-
NatuRi Corporation
Higgins, Robert F.; Fuller, Virginia A.Caso HBS-807027-EFinanzasNatuRi Corp. was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges, including securing funding for the organization. NatuRi had captured the attention of at least four potential investors willing to offer an investment. Its managers were challenged to weigh their...Desde 8,20 €
-
U.S. Food and Drug Administration
Higgins, Robert F.; Hamermesh, Richard G.; Fuller, Virginia A.Caso HBS-807050-ELiderazgo y Dirección de personasDescribes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.Desde 8,20 €
-
Odyssey Healthcare
Higgins, Robert F.; Fuller, Virginia A.; Raffat, UmerCaso HBS-809052-EIniciativa emprendedoraIn January 2001, Dick Burnham, CEO of Odyssey Healthcare, and Odyssey's Board of Directors were considering selling the hospice care company to a larger provider or making an initial public offering (IPO). With 38 hospice locations in 21 states, Odyssey had been providing care to the terminally ill since its first location opened in 1996. Since then, the company had grown rapidly through a series of acquisitions, development of new hospice locati...Desde 8,20 €
-
Kelly Solar
Bodily, Samuel E.; Lipson, Marc L.; Lichtendahl, Kenneth C. Jr.Caso DARDEN-F-1614-EFinanzasA small start-up company must make additional investments to maximize its firm value. But the company owner will not make this investment unless she can renegotiate outstanding debt claims. Solving this "debt overhang" problem through negotiation is the focus of the case. In this context, students are exposed to a variety of issues: the nature of financial claims, bargaining and negotiation fundamentals, and agency costs of debt.Desde 8,20 €